{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-073594","form_type":"8-K","ticker":"IRON","cik":"0001816736","company_name":"Disc Medicine, Inc.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.284022+00:00","generated_at":"2026-05-15T23:45:36.272274+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Disc Medicine reports FY2025 net loss $212.2M; receives CRL for bitopertin; cash runway into 2029","bullets":["Net loss of $212.2M for FY2025, up from $109.4M in FY2024; driven by higher R&D and SG&A costs.","Cash, cash equivalents and marketable securities of $791.2M as of Dec 31, 2025, up from $489.9M.","FDA issued Complete Response Letter for bitopertin in EPP in Feb 2026; Phase 3 APOLLO topline data expected Q4 2026.","Phase 2 data for DISC-0974 in MF anemia showed durable hemoglobin benefits across subgroups at ASH.","DISC-3405 Phase 2 in PV and Phase 1b in SCD ongoing; initial data expected 2H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-073594","json":"https://secwatch.observer/filing/0001193125-26-073594.json","markdown":"https://secwatch.observer/filing/0001193125-26-073594.md","text":"https://secwatch.observer/filing/0001193125-26-073594.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816736/000119312526073594/0001193125-26-073594-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816736/000119312526073594/iron-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:45:36.272274+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}